Secondary Logo

Journal Logo

November/December 2019 - Volume 39 - Issue 6
pp: 541-710

Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial

Veselinovic, Tanja; Scharpenberg, Martin; Heinze, Martin; More

Journal of Clinical Psychopharmacology. 39(6):550-560, November/December 2019.

Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial)

van der Schans, Jurjen; Hak, Eelko; Postma, Maarten; More

Journal of Clinical Psychopharmacology. 39(6):583-590, November/December 2019.

Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia: A Real-World Multicenter, Retrospective, Mirror-Image Study

Devrimci-Ozguven, Halise; Atmaca, Murad; Baran, Zeynep; More

Journal of Clinical Psychopharmacology. 39(6):604-610, November/December 2019.

A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia

Marder, Stephen R.; Singer, Carlos; Lindenmayer, Jean-Pierre; More

Journal of Clinical Psychopharmacology. 39(6):620-627, November/December 2019.

The Relationship Between Cumulative Exogenous Corticosteroid Exposure and Volumes of Hippocampal Subfields and Surrounding Structures

Nguyen, Duc M.; Yassa, Michael A.; Tustison, Nicholas J.; More

Journal of Clinical Psychopharmacology. 39(6):653-657, November/December 2019.